Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study
PRNewswire, 08 July 2020
Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced the initiation of the BB-301 Tissue Transduction Study in large animal subjects. Continue reading “Article: Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study”
